Heron Therapeutics Inc vs iShares Global Tech ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while iShares Global Tech ETF trades at $134. The key difference: iShares Global Tech ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | IXN | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.96 | $149.74 |
52-Week Low | $0.39 | $94.04 |
Enterprise Value | $189.36M | — |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
IXN trades at $132.95 with minimal daily movement (+0.25%). Technical indicators show a neutral to bearish bias with mixed signals from moving averages and oscillators. The stock faces resistance near $139-$141 while finding support around $133-$136. Recent analysis highlights strong technology sector exposure but cautions about elevated valuations and concentration risks in the portfolio.
The outlook remains cautious as current price levels reflect significant optimism about AI-driven growth. Investment opportunity lies in continued technology sector leadership, while risks include valuation concerns and sector concentration. Analyst sentiment leans neutral with expectations for clearer earnings growth catalysts before more bullish positioning.
Trailing returns across standard periods
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →